Search alternatives:
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
Showing 681 - 700 results of 65,940 for search '(( 5 non decrease ) OR ( 5 ((((point decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 0.84s Refine Results
  1. 681
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 682
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 683
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 684
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 685
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 686
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 687
    Data_Sheet_1_Early decrease of ventilatory ratio after prone position ventilation may predict successful weaning in patients with acute respiratory distress syndrome: A retrospective cohort study.zip

    Data_Sheet_1_Early decrease of ventilatory ratio after prone position ventilation may predict successful weaning in patients with acute respiratory distress syndrome: A retrospecti... by Zhichang Wang (2560528)

    Published 2022
    “…VR responders were defined as patients showing a decrease in VR of greater than or equal to 0.037 from the baseline to within 4 h after prone. …”
    Save to List
    Saved in:
  8. 688
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 689
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 690
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 691
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 692
    The Karolinska Sleepiness Scale (KSS) is a 9-point Likert scale, ranging from “extremely 1 = alert” to “9 = extremely sleepy–fighting sleep” [44].

    The Karolinska Sleepiness Scale (KSS) is a 9-point Likert scale, ranging from “extremely 1 = alert” to “9 = extremely sleepy–fighting sleep” [44]. by Marcel F. Hinss (14675457)

    Published 2024
    Save to List
    Saved in:
  13. 693
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 694
    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each combination of drill system (MIPS and MONO) and drilling protocol (DP1-DP5).

    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... by Marsel Ganeyev (21453399)

    Published 2025
    Save to List
    Saved in:
  15. 695
    Additional file 12 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 12 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  16. 696
    The waveforms of motor axons excitability parameters were presented as mean with SE for the paretic (black, n = 22), non-paretic (white, n = 22) limbs, and the sex and age-matched controls (grey, n = 22).

    The waveforms of motor axons excitability parameters were presented as mean with SE for the paretic (black, n = 22), non-paretic (white, n = 22) limbs, and the sex and age-matched... by Hung-Ju Chen (13842312)

    Published 2022
    Save to List
    Saved in:
  17. 697
    Additional file 8 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 8 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  18. 698
    Additional file 2 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 2 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  19. 699
    Additional file 9 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 9 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  20. 700
    Additional file 6 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 6 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:

Search Tools: